Business model and strategy

BioAlliance Pharma conceives and develops innovative products for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced on Euronext Paris market in 2005, the Company aims to become a leading player in these fields by combining innovation and patient needs.

The Company designs and manufactures innovative products, based on active pharmaceutical ingredients already recognized on the market with a proven efficacy and tolerance profile, as well as developing new entities. It more specifically targets diseases for which the medical needs are insufficiently met and where the phenomenon of drug resistance leads to particularly serious consequences.

Our teams have the key competencies required to identify, design, develop and register drugs in Europe and the USA. Our development choices enable us to balance the risks in our product portfolio and to accelerate market launch of our products.

Positioning itself on our targeted markets, with strategic experienced partners in Europe (Therabel), USA and Asia (Handok,NovaMed, Sosei) BioAlliance Pharma has consistent and experienced structures to organize the commercialization of its first product, Loramyc®, and to generate a recurring revenue stream.